Drug intelligence / Profile preview

EPZ005687

Development stage
Preclinical
Lead developer
Ipsen
Modality
Small Molecules
Administration
Intraperitoneal
01

Overview

EPZ005687 is a potent and selective small molecule inhibitor of the Polycomb Repressive Complex 2 (PRC2) subunit **EZH2** (Enhancer of Zeste Homolog 2). It acts as a S-adenosylmethionine (SAM) competitive inhibitor, preventing the trimethylation of histone H3 at lysine 27 (H3K27me3), a key epigenetic mark associated with gene silencing. Developed by Epizyme, EPZ005687 is highly selective for EZH2 over other histone methyltransferases and is effective against both wild-type and common lymphoma-associated mutant forms of the enzyme (such as Y641 and A677). While primarily utilized as a high-quality chemical probe in preclinical research, it has demonstrated the ability to inhibit the proliferation of EZH2-mutant lymphoma cells and modulate the tumor microenvironment, including enhancing the tumoricidal activity of macrophages in mesothelioma models.

02

Targets

EZH1EZH2 (Histone-lysine N-methyltransferase EZH2)

Beyond the preview

Go deeper on EPZ005687.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on EPZ005687.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call